Literature DB >> 7507004

Immune responses to bacterial polysaccharides: terminal epitopes are more immunogenic than internal structures.

C Fernandez1, E Sverremark.   

Abstract

Two types of dextran-protein conjugates can be produced depending on the size of dextran and the method chosen for coupling. Dextran of 4 x 10(4) molecular weight, randomly coupled to keyhole limpet hemocyanin evoked "incomplete" T cell-dependent (TD) immune responses. This atypical response only affected the dextran epitope since the response to the protein carrier was as expected for TD secondary immune responses. A second type of TD conjugates can be derived by coupling dextran (Dx) of 10(3) Da to the protein chicken serum albumin (CSA) via the reducing end (CSA-Dx-1). Immunization with CSA-Dx-1 induced the classical pattern of TD immune responses. Interestingly, immunization with CSA-Dx-1 favored the production of antibodies directed against terminal structures of the dextran molecule. These results were also confirmed at the hybridoma cell level. In contrast to other protein-dextran conjugates, CSA-Dx-1 was able to induce anti-dextran antibodies in CBA/N mice and in neonatal animals. We have interpreted these results to mean that conjugates exposing carbohydrate terminal nonreducing end structures could be more "physiological" and able to be recognized by helper T cells. This opens a new possibility for the production of vaccines against bacterial polysaccharides.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7507004     DOI: 10.1006/cimm.1994.1006

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  7 in total

1.  Immunogenicity of bacterial carbohydrates: cholera toxin modulates the immune response against dextran B512.

Authors:  E Sverremark; C Fernandez
Journal:  Immunology       Date:  1997-09       Impact factor: 7.397

2.  Capsular polysaccharide vaccine for Group B Neisseria meningitidis, Escherichia coli K1, and Pasteurella haemolytica A2.

Authors:  John B Robbins; Rachel Schneerson; Guilin Xie; Lars Å Hanson; Lars Åke-Hanson; Mark A Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-24       Impact factor: 11.205

3.  Critical Needs in Advancing Shigella Vaccines for Global Health.

Authors:  Calman A MacLennan; Kawsar R Talaat; Robert W Kaminski; Dani Cohen; Mark S Riddle; Birgitte K Giersing
Journal:  J Infect Dis       Date:  2022-05-04       Impact factor: 7.759

4.  Unresponsiveness following immunization with the T-cell-independent antigen dextran B512. Can it be abrogated?

Authors:  E Sverremark; C Fernandez
Journal:  Immunology       Date:  1998-11       Impact factor: 7.397

5.  Local and systemic antibody responses to dextran-cholera toxin B subunit conjugates.

Authors:  C Bergquist; T Lagergård; M Lindblad; J Holmgren
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

Review 6.  Impact and Control of Sugar Size in Glycoconjugate Vaccines.

Authors:  Giuseppe Stefanetti; Calman Alexander MacLennan; Francesca Micoli
Journal:  Molecules       Date:  2022-09-29       Impact factor: 4.927

7.  Protection against Experimental Melioidosis with a Synthetic manno-Heptopyranose Hexasaccharide Glycoconjugate.

Authors:  Andrew E Scott; William J Christ; Alison J George; Margaret G M Stokes; Gregory J S Lohman; Yuhong Guo; Matthew Jones; Richard W Titball; Timothy P Atkins; A Stewart Campbell; Joann L Prior
Journal:  Bioconjug Chem       Date:  2016-05-17       Impact factor: 4.774

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.